16 December 2025
16 December 2025 Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive…
10 December 2025
GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA · Designation supported by early clinical data showing durable responses…
18 July 2025
A SIGNIFICANT STEP IN THE EXECUTION OF OUR STRATEGIC PLAN (London UK, 18 July 2025): Reckitt Benckiser Group plc (“Reckitt”) announces it has entered…
7 March 2025
A landmark year Annual results for the year ended 31 December 2024 Financial highlights as at 31 December 2024 2024 2023 Net Assets…
13 February 2025
2024 Full Year Results Improved performance led by volume growth and gross margin expansion Underlying performance GAAP measures (unaudited) 2024 vs 2023…
20 January 2025
European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer · Expanded approval includes MMRp/MSS tumours, which represent…
16 December 2024
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer · Regulatory designation based on promising preliminary clinical…
21 November 2024
HALMA plc HALF YEAR RESULTS 2024/25 Halma plc, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for…